Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Vaniqa er større end risiciene ved behandling af ansigtsbehåring hos kvinder.
The Committee for Medicinal products for Human Use (CHMP) decided that Vaniqa’ s benefits are greater than its risks for the treatment of facial hirsutism in women.